Department of Hematology, The Second Hospital of Dalian Medical University, Dalian, China.
The Third Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China.
BMC Oral Health. 2022 Sep 5;22(1):386. doi: 10.1186/s12903-022-02410-z.
Langerhans cell histiocytosis (LCH) is a heterogeneous neoplastic disorder that is rarely seen in patients aged 60 years and older. It is reported that elderly patients with LCH have a higher chance of having malignancies. In the oral cavity, patients with LCH can present with mucosal ulcers and extensive osteolysis, making it difficult for clinicians to make a proper diagnosis.
We reported an 82-year-old Chinese woman with oral symptoms as the first presentation of LCH, and eventually developed acute myeloid leukemia (AML). She suffered diffuse ulcers involving the entire gingival mucosa and the left half hard palate, and had lost several teeth. Genomic DNA sequencing of the cells from LCH revealed multiple mutations in TET2, BRAF, SRSF2, NRAS, MAP2K4 and so on. The patient declined the BRAF inhibitor (Vemurafenib). Although a dramatic improvement of the oral ulcers was achieved after symptomatic treatment, the patient developed acute myeloid leukemia (AML) and died.
This report presented the diagnostic difficulties of LCH with oral manifestations and highlighted the importance of radiological assessments and laboratory tests. Moreover, many of the mutations detected in our LCH patient are frequently seen in AML, suggesting that AML and LCH cells in this patient share the same origin.
朗格汉斯细胞组织细胞增生症(LCH)是一种异质性肿瘤性疾病,在 60 岁及以上的患者中很少见。据报道,老年 LCH 患者发生恶性肿瘤的几率更高。在口腔中,LCH 患者可表现为黏膜溃疡和广泛的骨质溶解,这使得临床医生难以做出正确的诊断。
我们报告了一例 82 岁的中国女性,以口腔症状为 LCH 的首发表现,最终发展为急性髓系白血病(AML)。她患有弥漫性溃疡,累及整个牙龈黏膜和左半硬腭,并已失去几颗牙齿。LCH 细胞的基因组 DNA 测序显示 TET2、BRAF、SRSF2、NRAS、MAP2K4 等多个基因突变。该患者拒绝使用 BRAF 抑制剂(vemurafenib)。尽管在对症治疗后口腔溃疡得到了显著改善,但患者还是发展为急性髓系白血病(AML)并死亡。
本报告介绍了以口腔表现为首发症状的 LCH 的诊断困难,并强调了影像学评估和实验室检查的重要性。此外,我们在 LCH 患者中检测到的许多突变也经常见于 AML,这表明该患者的 AML 和 LCH 细胞起源相同。